<DOC>
	<DOC>NCT02053896</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of ISU302 in patients with Type 1 Gaucher disease previously treated with Imiglucerase.</brief_summary>
	<brief_title>A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease</brief_title>
	<detailed_description />
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Patient diagnosed with type1 Gaucher disease Patient who was stably treating Gaucher disease with Cerezyme® and who was maintaining the usage and dosage of Cerezyme® for at least 6 months prior to study drug administration Patient aged 2 years or higher Female patient with contraception during the study period (oral or injectable contraceptive hormones, intrauterine device, physical devices using condom, sponge form, jelly, and femidom, and abstinence) Patient who signed the informed consent form after hearing the detailed explanation about this study Definition of the stable treatment of type1 Gaucher disease: No neurologic deficit Normal hemoglobin concentration, and platelet count that has increased to ≥100,000/㎣, or maintained to 100,000/㎣ Normal or no deteriorated bone mineral density Normal or no deteriorated splenomegaly or hepatomegaly Patient who participated in other clinical studies within 90 days before study drug administration Patient with unstable hemoglobin and platelet counts for at least 6 months before study drug administration Patient with hypersensitivity to Cerezyme® Patient positive to HIV antibody, hepatitis B antigen, and hepatitis C antibody Patient with Fe, folic acid, or vitamin B12deficcient anemia Patient who received miglustat within 6 months before study drug administration Patient who received erythrocyte growth factor or chronic systemic corticosteroids within 6 months before study drug administration Patient who had clinically significant splenic obstruction within 12 months before study drug administration Pregnant or lactating patient Patient who had serious concurrent diseases such as infectious diseases or drugaddicted patient Patient who was considered inappropriate for this study by the investigators or subinvestigators</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Type I Gaucher</keyword>
	<keyword>ISU302</keyword>
	<keyword>Imiglucerase</keyword>
</DOC>